HDFC Bank Limited 2025 Q2 – Results – Earnings Call Presentation (NYSE:HDB)
Q2: 2024-10-19 Earnings AbstractEPS of $0.78 beats by $0.28 | Income of $4.95B (8.04% Y/Y) misses by $27.18MThis text was ...
Tag: Presentation
EQT AB (publ) 2024 Q3 – Results – Earnings Call Presentation (OTCMKTS:EQBBF)
This text was written byObserveLooking for Alpha's transcripts crew is answerable for the event of all of our transcript-related tasks. ...
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines By Investing.com
Up to date Section 1 dose-escalation information from ARROS-1 and ALKOVE-1 scientific trials proceed to help potential best-in-class profiles for ...
Veeva Systems Inc. 2025 Q2 – Results – Earnings Call Presentation (NYSE:VEEV)
This text was written byComply withSearching for Alpha's transcripts group is liable for the event of all of our transcript-related ...
Medtronic plc 2025 Q1 – Results – Earnings Call Presentation (NYSE:MDT)
This text was written byObserveSearching for Alpha's transcripts group is liable for the event of all of our transcript-related tasks. ...
Blackstone Secured Lending Fund. 2024 Q2 – Results – Earnings Call Presentation (NYSE:BXSL)
This text was written byComply withSearching for Alpha's transcripts group is liable for the event of all of our transcript-related ...
Taylor Wimpey plc 2024 Q2 – Results – Earnings Call Presentation (OTCMKTS:TWODF)
This text was written byObserveSearching for Alpha's transcripts staff is liable for the event of all of our transcript-related initiatives. ...
Woodward, Inc. 2024 Q3 – Results – Earnings Call Presentation (NASDAQ:WWD)
This text was written byObserveSearching for Alpha's transcripts crew is liable for the event of all of our transcript-related tasks. ...
Essential Properties Realty Trust, Inc. 2024 Q2 – Results – Earnings Call Presentation (NYSE:EPRT)
This text was written byObserveLooking for Alpha's transcripts staff is chargeable for the event of all of our transcript-related initiatives. ...
™E Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024 By Investing.com
BERLIN--(BUSINESS WIRE)--™E Pharma N.V. (Euronext Progress Paris: AL™E), a clinical-stage biotechnology firm targeted on growing novel therapies for remedy of ...